Enhancing Molecular Testing for Metastatic Colorectal Cancer Patients RFP

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Monday 6th, May 2024

External Deadline: Thursday 9th, May 2024


Pfizer’s Global Medical Grants (GMG) program supports the global healthcare community’s independent initiatives, e.g., research, quality improvement or education, to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Colorectal Cancer Canada (CCC) is Canada’s patient led not-for-profit patient association dedicated to colorectal cancer awareness and education, support for patients and their caregivers, and advocacy on their behalf and aspires to reduce the incidence and mortality of colorectal cancer in Canada while improving the quality of life of patients, their families and their caregivers. Founded in 1998, CCC has been an advocate for Canadian CRC patients for over twenty-five years. Through the Get Personal project and numerous other educational initiatives, CCC has prioritized the improvement of timely access to molecular testing for Canadian mCRC patients among its many important objectives.

Pfizer Canada and Colorectal Cancer Canada are collaborating to offer a new funding opportunity seeking proposals for Quality Improvement (QI) initiatives focusing on empowering Canadian centres to develop or optimize molecular testing for patients with mCRC. In this Request for Proposals (RFP), applicants are encouraged to review and consider the Funding Opportunities described below to support and develop their innovative ideas aimed at streamlining molecular testing processes for metastatic colorectal cancer. Applicants are encouraged to showcase how their ideas can have sustainable and measurable impact on molecular testing, and by extension on cancer care for patients in Canada.

For all QI proposals, the grant requester and ultimately, the grantee, is responsible for the design, implementation, sponsorship and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. As the commercial supporter, Pfizer colleagues must not be involved in any aspect of project development or implementation.

Date RFP Issued: March 7, 2024

Geographic Scope: Canada

Clinical Area: Metastatic colorectal cancer (mCRC)

Link to full RFP: Enhancing Molecular Testing for Metastatic Colorectal Cancer Patients

Application Due Date: May 9, 2024

Specific Area of Interest: Topics of highlighted interest include, but are not limited to:

  •  – Achieving rapid turnaround time for molecular testing for metastatic colorectal cancer patients (projects proposals may also encompass other tumour types).
  • – Projects addressing effectiveness and/or quality of pre- and/or post-analytical steps of established assays.
  • – Projects that aim to achieve access to in-house molecular testing in non-academic or community centres.
  • – Innovative approaches to molecular testing with a focus on sustainability.
  • – Creating a sustainable workflow and operation based on the applicant institutional needs, for example: training, instrument implementation…etc.
  • – Improve health equity in access to timely molecular testing in CRC and other tumour types by addressing disparities for patients marginalized due to age, race, geography, income or other factors.
    – QI projects that address biomarker testing with endpoints including, but not limited to: clinical effectiveness/utility; turnaround times; analytical validity; cost-effectiveness; system level efficiencies and data sharing; social determinants

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Don Rodriguez, Grant Officer (Don.Rodriguez@pfizer.com).

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: March 14, 2024